Nuvectis Pharma, Inc. Increase (Decrease) in Other Current Assets
Nuvectis Pharma, Inc. (NVCT) reported Increase (Decrease) in Other Current Assets of $141.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherCurrentAssets · last filed 2026-08-04
- Nuvectis Pharma, Inc. increase (decrease) in other current assets for the quarter ending 2026-06-30 was -$52.00K.
- Nuvectis Pharma, Inc. increase (decrease) in other current assets for the quarter ending 2026-03-31 was $193.00K, a 8.10% decline year-over-year.
- Nuvectis Pharma, Inc. increase (decrease) in other current assets for the quarter ending 2025-12-31 was -$70.00K.
- Nuvectis Pharma, Inc. increase (decrease) in other current assets for the quarter ending 2025-09-30 was -$69.00K.
- Nuvectis Pharma, Inc. increase (decrease) in other current assets for fiscal 2025 was $1.00K, a 93.33% decline from fiscal 2024.
- Nuvectis Pharma, Inc. increase (decrease) in other current assets for fiscal 2024 was $15.00K.
- Nuvectis Pharma, Inc. increase (decrease) in other current assets for fiscal 2023 was -$353.00K, a 209.97% decline from fiscal 2022.
- Nuvectis Pharma, Inc. increase (decrease) in other current assets for fiscal 2022 was $321.00K, a 252.75% increase from fiscal 2021.
| Period end | Increase (Decrease) in Other Current Assets 3 month | Increase (Decrease) in Other Current Assets 6 month | Increase (Decrease) in Other Current Assets 9 month | Increase (Decrease) in Other Current Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$52.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $141.00K 10-Q · filed 2026-08-04 | $71.00K derived: sum of 3 quarters · filed 2026-08-04 | $2.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $193.00K 10-Q · filed 2026-05-05 | $123.00K derived: sum of 2 quarters · filed 2026-05-05 | $54.00K derived: sum of 3 quarters · filed 2026-05-05 | -$16.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | -$70.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | -$139.00K derived: sum of 2 quarters · filed 2026-02-11 | -$209.00K derived: sum of 3 quarters · filed 2026-08-04 | $1.00K 10-K · filed 2026-02-11 |
| 2025-09-30 | -$69.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$139.00K derived: sum of 2 quarters · filed 2026-08-04 | $71.00K 10-Q · filed 2025-11-04 | $7.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | -$70.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $140.00K 10-Q · filed 2026-08-04 | $76.00K derived: sum of 3 quarters · filed 2026-08-04 | $32.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $210.00K 10-Q · filed 2026-05-05 | $146.00K derived: sum of 2 quarters · filed 2026-05-05 | $102.00K derived: sum of 3 quarters · filed 2026-05-05 | $34.00K derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | -$64.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | -$108.00K derived: sum of 2 quarters · filed 2026-02-11 | -$176.00K derived: sum of 3 quarters · filed 2026-02-11 | $15.00K 10-K · filed 2026-02-11 |
| 2024-09-30 | -$44.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$112.00K derived: sum of 2 quarters · filed 2025-11-04 | $79.00K 10-Q · filed 2025-11-04 | -$65.00K derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | -$68.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $123.00K 10-Q · filed 2025-08-05 | -$21.00K derived: sum of 3 quarters · filed 2025-08-05 | -$159.00K derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | $191.00K 10-Q · filed 2025-05-06 | $47.00K derived: sum of 2 quarters · filed 2025-05-06 | -$91.00K derived: sum of 3 quarters · filed 2025-05-06 | -$490.00K derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | -$144.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | -$282.00K derived: sum of 2 quarters · filed 2025-02-25 | -$681.00K derived: sum of 3 quarters · filed 2025-02-25 | -$353.00K 10-K · filed 2025-02-25 |
| 2023-09-30 | -$138.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | -$537.00K derived: sum of 2 quarters · filed 2024-11-05 | -$209.00K 10-Q · filed 2024-11-05 | -$1.02M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | -$399.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$71.00K 10-Q · filed 2024-08-06 | -$885.00K derived: sum of 3 quarters · filed 2024-08-06 | -$325.00K derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $328.00K 10-Q · filed 2024-05-07 | -$486.00K derived: sum of 2 quarters · filed 2024-05-07 | $74.00K derived: sum of 3 quarters · filed 2024-05-07 | -$182.00K derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | -$814.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | -$254.00K derived: sum of 2 quarters · filed 2024-03-05 | -$510.00K derived: sum of 3 quarters · filed 2024-03-05 | $321.00K 10-K · filed 2024-03-05 |
| 2022-09-30 | $560.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $304.00K derived: sum of 2 quarters · filed 2023-11-08 | $1.14M 10-Q · filed 2023-11-08 | |
| 2022-06-30 | -$256.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $575.00K 10-Q · filed 2023-08-09 | ||
| 2022-03-31 | $831.00K 10-Q · filed 2023-05-10 | |||
| 2021-12-31 | $91.00K 10-K · filed 2023-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 |